Fabrizio Stocchi, MD, PhD, IRCCS San Raffaele Rome, Sapienza University of Rome, Rome, Italy, gives an insight into the new agents available for the treatment of Parkinson’s disease (PD). Safinamide, opicapone, sublingual apomorphine, inhalation levodopa, and slow-release preparation of levodopa have already entered or are just entering the PD market. Safinamide is an inhibitor of monoamine oxidase-B (MAO-B) and opicapone is an inhibitor of catechol-O-methyltransferase (COMT), both of which act to help levodopa work better through reduction of necessary oral levodopa intake and "OFF" times. Opicapone may also be able to reduce the risk of motor fluctuations and dyskinesias in patients who are not already suffering with these symptoms. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.
